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Abstract
Summary Most post-vertebroplasty new-onset adjacent
vertebral compression fractures (VCFs) occur within 2–
3 months, and antiresorptive agents do not significantly
reduce the risk of their occurrence. In opposite mechanism,
teriparatide directly stimulates bone formation and
improves bone strength and quality faster. The therapeutic
effect of teriparatide is better than that of vertebroplasty
combined with an antiresorptive treatment and is a
potentially useful therapy for new-onset adjacent VCFs
after vertebroplasty.
Introduction Following vertebroplasty, patients are at
increased risk of new-onset adjacent-level VCFs. The
therapeutic effect of antiresorptive agents is too slow, and
they are associated with the risk of new VCFs. Teripara-
tide markedly increases bone formation and strength and
reduces the incidence of new-onset VCFs. This prospec-
tive cohort study compared the therapeutic effects of
teriparatide with those of combined vertebroplasty and an
anti-resorber for treating new-onset adjacent VCFs after
vertebroplasty.
Methods Fifty patients with adjacent VCFs were randomly
assigned to two groups: teriparatide only (group A) and
additional vertebroplasty combined with an antiresorptive
agent (group B). Relevant clinical data of the two groups
were prospectively compared.
Results The 22 patients in group A were at higher risk of
new VCFs than those in group B (22 patients); they were
older and had more pre-existing fractures (p<0.05). Patients
treated with teriparatide had a significantly lower incidence
of new-onset VCFs (odds ratio=0.21; 95% confidence
interval, 0.02–2.10). Teriparatide-mediated VCF reduction
was 78.57%, which was markedly better than that of group
B. The teriparatide group had a significant decrease in the
visual analog scale and an increase in the Japanese
Orthopedic Association low back pain score after 6 months
of treatment (p<0.05). The increase in lumbar spine BMD
was marked in the teriparatide group (21.70% vs. 6.87%)
after an 18-month treatment.
Conclusions Treatment of post-vertebroplasty adjacent
VCFs with teriparatide (no new vertebroplasty) was more
effective than that of repeated vertebroplasties combined
with an anti-resorber.
Keywords Adjacent vertebral fracture.Antiresorptive
agent.Teriparatide.Vertebral compression fracture.
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Vertebral compression fractures (VCFs) are the most
common fragility fracture and are the hallmark of osteopo-
rosis. Osteoporotic VCFs are associated with a significantly
decreased quality of life and increased mortality in the
elderly [1, 2]. Percutaneous vertebroplasty (PVP) has been
performed for more than 10 years to treat painful
osteoporotic VCFs. For patients with acute osteoporotic
VCFs and persistent pain, PVP is effective and safe. Pain
relief after vertebroplasty is immediate, sustained for at
least 1 year, and is significantly greater than that achieved
with conservative treatment, at an acceptable cost [3].
Nonetheless, clinical studies suggest patients who undergo
vertebroplasty/kyphoplasty have a greater risk of new-onset
VCFs in adjacent and non-adjacent spinal levels compared
to patients with prior VCFs who did not undergo either
procedure [4, 5]. Following vertebroplasty, patients are at
an increased risk of new-onset adjacent-level VCFs, and
when these fractures occur, they occur sooner than non-
adjacent-level fractures [6]. Most new adjacent VCFs
occurred within 3 months of PVPs [6, 7]. The relative risk
of adjacent-level fracture was 4.62 times that of non-
adjacent-level fracture. If treatment to prevent VCFs was
not immediate and effective, new-onset VCFs occurred
repeatedly within a few years after PVP [6–8]. Further
fracture prevention is as important as pain relief in treating
severe osteoporotic VCFs. Vertebroplasty does not play a
role in further fracture prevention.
Antiresorptive agents are widely used to treat osteopo-
rosis. Data from clinical trials show that antiresorptive
agents (raloxifene and alendronate) reduce the risk of
vertebral fracture by 40% to 50% after 3 years of treatment
[9, 10]. Nonetheless, in the treatment of severely osteopo-
rotic patients, the therapeutic effect of antiresorptive agents
is too slow, and the use of these agents is associated with a
high risk of new-onset fractures.
Teriparatide (rDNA origin) injection [recombinant
human PTH(1–34)] is the first bone anabolic agent for
the treatment of osteoporosis. Teriparatide administered
once daily through subcutaneous self-injection results in
a rapid and greater increase in vertebral bone mineral
d e n s i t y( B M D )a n dad e c r e a s e dr i s ko fv e r t e b r a la n d
non-vertebral fractures in postmenopausal women and
m e nw i t ho s t e o p o r o s i s[ 11, 12]. Teriparatide, with a
mechanism different from that of antiresorptive agents,
preferentially increases bone formation through direct
early stimulation of osteoblasts. This increase in new bone
formation results in a positive bone balance at the level of
individual bone multicellular units and improved bone
microarchitecture and quality [13]. We hypothesized that
treating the adjacent VCF after PVP requires a faster
increase in new bone formation and improved bone
strength and quality. This prospective cohort study aimed
to assess the immediate and mid-term efficacy and safety
of teriparatide for treatment of new-onset adjacent com-
pression fractures after PVP. We prospectively compared
the therapeutic effects of teriparatide and combined
vertebroplasty with an antiresorptive agent in fracture
prevention, BMD increase, and sustained pain relief.
Patients and methods
Patients
All patients provided informed written consent before
participating. We identified 50 patients who had adjacent
VCFs after vertebroplasty from November 2007 to December
2010. VCF was diagnosed based on radiologic findings in all
patients. All patients underwent magnetic resonance imaging
(MRI) examinations for definitive diagnosis of new-
onset osteoporotic VCFs when they had their first
painful VCF. The exclusion criteria were spinal cancer,
neurologic complications, osteoporotic vertebral collapse
of greater than 90%, fracture through or destruction of
the posterior wall, retropulsed bony fragmentation or
bony fragments impinging on the spinal cord, medical
conditions that would make the patient ineligible for
emergency decompressive surgery if needed, and a
likelihood of noncompliance with follow-up.
All subjects completed a baseline questionnaire that
inquired about use of alcohol and cigarettes, rheumatic
arthritis, history of spine or other bone fractures, and
history of corticosteroid use. The patients were randomly
assigned to either group A or group B (if the last number of
their identification card was odd, they were assigned to
group A (24 patients); if the last number was even, they
were assigned to group B) (Fig. 1). Two patients in group A
refused to accept daily subcutaneous injections of teripara-
tide and were excluded from this study. The remaining 22
patients in group A received subcutaneous injections of
teriparatide (20 μg) once daily and daily supplementation
with calcium (1,000–1,500 mg) and vitamin D (800–
1,000 IU) throughout the study. These 22 patients were
monitored for at least 20 months beginning with the
diagnosis of post-PVP adjacent VCF (range, 20–36 months;
mean, 25.05±3.42 months).
Twenty-six patients were assigned to group B, three were
lost to follow-up, and one experienced a large middle
cerebral artery infarction during the follow-up period.
These four patients were excluded from the analysis. The
remaining 22 patients in group B were given antiresorptive
agents (alendronate or raloxifene) combined with calcium
supplementation (1,000–1,500 mg) and vitamin D (800–
1,000 IU) for osteoporosis treatment for at least 20 months
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male patients were given alendronate treatment. For the
female patients, if the last number of the medical record
number was odd, raloxifene was used to treat the
osteoporosis; if the last number was even, alendronate
was used. The oral dosage of alendronate was 70 mg once
weekly and that of raloxifene was 60 mg once daily. The
antiresorptive agents were not combined. Patients who
experienced side effects or had low compliance with their
assigned antiresorptive agent were switched to the other
agent. Two women had severe epigastric pain and nausea,
and one woman had severe constipation after taking
alendronate; these three patients were switched to ralox-
ifene treatment. Two women had severe hot flashes, and
one had intolerable leg cramps after taking raloxifene.
These three women were switched to alendronate treatment.
One of these antiresorptive agents had to be used for
osteoporosis treatment for at least 18 months after an
adjacent osteoporotic VCF occurred. If the patients in either
group experienced new-onset VCFs, the painful vertebrae
were located by a combination of local tenderness at the
fracture site and the typical appearance of the fracture on
radiographic (or MRI) evaluation. The indications for PVP
were intense focal back pain, progressive kyphosis, and
failure of conservative medical therapy in patients who had
worn an orthosis for at least 1 month, if their visual analog
scale (VAS) was less than 7. If the patient's VAS score was
greater than 7 and conservative therapy for more than
2 weeks had failed, PVP was performed. The follow-up
period for the 22 patients in group B was 24.63±
3.48 months (range, 20–36 months), beginning at the time
post-PVP adjacent VCF was diagnosed.
Clinical data on patients in both groups included age,
sex, number of pre-existing VCFs, baseline BMD, bone
mass index (BMI), the volume of polymethylmethacrylate
(PMMA) injected during the first PVP, and the duration
between new-onset VCFs (including adjacent and non-
adjacent). For the vertebral reduction ratio (using a
quantitative assessment) [14], we measured the anterior
(Ha), posterior (Pa), adjacent posterior (Hpa), and middle
(Hm) vertebral body height. In addition, the following
ratios were calculated: anterior–posterior ratio = Ha/Hp,
middle-posterior ratio = Hm/Hp, and posterior–posterior
adjacent ratio = Hp/Hpa. The lowest value was defined as
the vertebral reduction ratio.
Outcome assessment
Anteroposterior and lateral lumbar spine radiographs were
obtained at baseline to determine whether at least two
evaluable vertebrae in the lumbar spine region (L1–L4)
were present in each patient fulfilling BMD entry criteria.
Areal bone mineral density was measured in all patients by
dual energy X-ray absorptiometry (DXA) using Hologic
(Hologic Inc, Bedford, MA) or GE-lunar (Lunar Prodigy,
GE Lunar Corp., Madison, USA) densitometers at baseline
and at 6, 12, and 18 months after administration of
teriparatide in group A and antiresorptive therapy in group
B. Lumbar spine (L1–L4) measurements were obtained,
and vertebrae with structural change or artifacts were
excluded. Diagnoses were not made based on single
vertebral bodies. The densitometries for each patient
consistently used the same DXA system, acquisition
methods, software, and young normal databases.
The Huskisson VAS [15] was used to estimate pain
perception at baseline and at 1, 6, 12, and 18 months after
administration of teriparatide. The standard scale from 0
(no pain) to 10 (intolerable pain) was used for pain analysis.
The Japanese Orthopedic Association (JOA) low back pain
scores [16] for clinical symptoms of patients with lower
back pain were calculated at baseline and at 1, 6, 12, and
18 months. The JOA scores ranged from −6t o2 9p o i n t s ;
the higher the score, the more normal is the patient's
overall status. The JOA score is valuable for measuring
improvement following treatment.
Statistical analysis
Results are presented as means ± SD. Independent data,
including age, body mass index, pre-existing fracture,
vertebral body reduction ratio, injected PMMA quantity,
Fig. 1 Algorithm for the treatment of adjacent vertebral compression
fractures. (*One patient in the teriparatide group experienced new-
onset adjacent VCF. He did not receive vertebroplasty due to the VAS
score less than 7 and the symptoms subsided after 2 weeks after
continuing teriparatide treatment. **Four patients in the antiresorptive
agents combined with vertebroplasty group received additional
vertebroplasties.) VCF vertebral compression fracture, VP vertebro-
plasty, KP kyphoplasty, VAS visual analog scale, Loss loss of follow-
up, Infarction large middle cerebral artery infarction
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scores, were compared between groups A and B using the
Mann–Whitney U test. The VAS scores and JOA scores at
baseline and at 1, 6, 12, and 18 months after treatment were
compared using Student's t test. A one-sample t test was
also used to measure changes in BMD and T-score.
Differences in sex ratios between the two groups were
compared using the chi-square test. Statistical analyses
were performed using SPSS (version 12.0; SPSS Inc,
Chicago, IL). Unless otherwise stated, a p value <0.05
was taken as significant.
Results
Group A comprised 22 patients who received 18 months of
teriparatide therapy for new-onset adjacent VCFs after
PMMA vertebroplasty. The comparison group (group B)
included 22 patients who received antiresorptive agents for
at least 18 months. All 44 patients received vitamin D and
calcium supplementation. Table 1 summarizes the compar-
ison of clinical data between the two groups. There was no
significant difference in male-to-female ratio, body mass
index, injected volume of PMMA, steroid use, current
smoking, alcohol drinking, or rheumatic arthritis between
the two groups. The mean age of the patients in group A
(75.59±6.28) was significantly older than that of the
patients in group B (70.55±4.10, p=0.002). The number
of pre-existing VCFs was significantly higher in group A
(3.01±0.87) than in group B (2.17±0.66, p=0.004). The
baseline BMD was 0.5796±0.0816 g/cm
2 in group A and
0.6245±0.1026 g/cm
2 in group B (p=0.056). The vertebral
body reduction ratio in group A was 48.68%±11.94%,
while in group B, it was 49.82%±12.19% (p=0.756).
Teriparatide (20 μg) was subcutaneously injected once
daily, and oral calcium and vitamin D supplements were
given for at least 18 months to the 22 patients in group A.
Two patients experienced mild leg muscle spasms or
cramps after injection of teriparatide. The symptoms
subsided within 5 days in one patient and within 14 days
in the other. The mean VAS score at baseline was 8.27±1.16
(range, 6–10) (Fig. 2). After 1 month of treatment, the mean
VAS score was 4.23±0.97. The mean VAS score decreased
to 2.23±0.61 after 6 months, 1.20±0.96 after 12 months,
and 1.18±0.80 (range, 0–3) after 18 months of teriparatide
treatment (p=0.001, all the differences between baseline
and 6 months, 6 months and 12 months, and 12 months and
18 months were significant). Four patients had VAS scores
of 0 and, six patients were analgesic free at the 18-month
follow-up.
In group B, three patients had intolerable side effects and
needed to change antiresorptive agents. The mean VAS
score was 8.13±0.95 (range, 6–10) prior to treatment and
4.09±1.31 1 months after PVP plus antiresorptive agent
treatment. The mean VAS score was 3.27±1.42 after
6 months, 2.95±1.56 after 12 months, and 3.14±1.58
(range, 1–6) after 18 months of PVP plus antiresorptive
treatment (Fig. 2). The VAS scores of all patients in group B
were >0, and two patients were analgesic free at 18 months
of follow-up. The VAS scores of the two groups were
significantly different at each time point, beginning at
6 months (p<0.05).
The mean JOA score in group A was 9.95±4.02 prior to
treatment and 18.59±3.28 after 1 month of treatment. A
significant increase in the mean JOA score occurred after
1 month of treatment with teriparatide. The mean JOA
score was 21.23±2.62 (range, 16–24; p=0.001) after
6 months and 24.18±2.79 after 12 months of teriparatide
Group A Group B p value
Age (years) 75.95±6.28 70.55±4.10 0.002*
Gender (F/M) 20:2 20:2 1.000
BMI 23.16±3.43 25.34±4.35 0.367
Pre-existing fracture 3.01±0.87 2.17±0.66 0.004*
VB reduction ratio (%) 48.68±11.94 49.82±12.19 0.756
PMMA amount (ml) 4.64±1.32 4.68±1.37 0.572
Baseline BMD (T-score) 0.5796±0.0816 0.6245±0.1026 0.056
(−3.76±0.71) (−3.45±0.73) 0.073
Baseline JOA score 9.95±4.02 11.59±3.46 0.115
Baseline VAS score 8.27±1.16 8.13±0.95 0.888
Steroid use 5 4 0.446
Current smoking 5 5 1.000
Alcohol 6 5 0.716
Rheumatic arthritis 2 2 1.000
Follow-up period (months) 25.05±3.42 24.63±3.48 0.517
Table 1 Comparison of clinical
data between groups A and B
*p<0.05
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after 18 months of teriparatide treatment (p=0.001, all the
differences between baseline and 6 months, 6 months and
12 months, and 12 months and 18 months were significant).
Three patients had full JOA scores, and four were analgesic
free at 20 months of follow-up.
In group B, the mean JOA score was 11.59±3.46 prior to
treatment, 17.32±3.41 after 1 month of treatment, 18.09±
2.58 (range, 16–24; p=0.001) after 6 months of vertebro-
plasty combined with an antiresorptive treatment, and
19.41±2.68 after 12 months of teriparatide treatment. After
18 months of treatment, the mean JOA score did not
increase, but decreased slightly to 18.80±3.33 (range, 13–
26). No patient had a full JOA score, and two were
analgesic free at 20 months of follow-up. The mean JOA
scores of the two groups were significantly different at each
time point, beginning at 6 months (p<0.05).
The VAS score in group A was significantly lower than
that in group B after 6 months of treatment (p=0.003).
Similarly, the JOA score in group A was significantly higher
than in group B after 6 months (P=0.000).
In group A (teriparatide group), only one patient
developed a new-onset adjacent compression fracture after
teriparatide treatment. That patient was a 72-year-old
woman with severe osteoporosis (T-score, −4.30) who
underwent vertebroplasty for an L2 compression fracture.
A new-onset adjacent VCF at L3 occurred 78 days after
PVP. The patient was started on teriparatide treatment on
the day the new-onset fracture was diagnosed. Unfortu-
nately, she experienced severe back pain again, and a plain
lumbar spine X-ray film demonstrated a new L1 adjacent
VCF after 27 days of teriparatide treatment. Teriparatide
was continuously administrated. The intractable back pain
subsided 2 weeks after teriparatide treatment. No additional
VCF occurred, and the patient was symptom free at
33 months of follow-up. In group B, four (18.18%) patients
developed new-onset VCFs (five vertebrae) after the second
PVP, and received a third PVP. Among those four patients,
one (25%) developed new-onset VCFs after the third PVP
and required a fourth PVP (Fig. 3). The new-onset VCFs
involved six vertebrae: four were adjacent VCFs (67%),
and two were non-adjacent VCFs. Surgical complications
resulting in the need for additional PVPs (six vertebrae)
Fig. 2 The mean VAS pain score and JOA lower back pain score
changes in groups A and B. Data are expressed as mean ± SD. The
decrease in VAS and the increase in JOA scores were significant
between groups A and B at 6, 12, and 18 months, respectively.
(*p<0.05, ★p<0.01) VAS visual analog scale, JOA Japanese Ortho-
pedic Association
Fig. 3 The patient wasa 74-year-
old woman with severe osteopo-
rosis (T-score, −3.70) who under-
went PVP for T10 and T12 VCFs
(a). A new-onset adjacent VCF
at T9 occurred 68 days after PVP,
and the patient underwent a
second PVP (b). The patient
began alendronate treatment on
the day the new-onset fracture
was diagnosed. She experienced
severe back pain again, and a
plain lumbar spine X-ray dem-
onstrated new L1 and L2 adja-
cent VCFs 43 days after the
second PVP, so she underwent a
third PVP due to intractable back
pain (c). Unfortunately, a new
T11 adjacent VCF occurred
33 days later, and a fourth PVP
was performed 2 weeks later,
after which minor bone cement
extravasation occurred (d)
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decompressive laminectomy, and two minor bone cement
extravasations. Muscle power in both legs of the patient
who underwent decompressive laminectomy recovered
gradually but not fully during a 6-month rehabilitation
program. Overall, teriparatide reduced the risk of new-onset
VCFs after vertebroplasty (OR=0.21; 95% CI, 0.02–2.10).
The fracture risk reduction associated with teriparatide
treatment was markedly better than that with antiresorptive
agents; the relative risk reduction was 78.57%.
The BMD and T-score of the lumbar spine were
estimated prior to and after 6, 12, and 18 months of
treatment. All 22 patients in group A underwent BMD
examination before administration of teriparatide. One
patient had an L2 VCF and an adjacent L3 VCF before
treatment with teriparatide and experienced a new adjacent
L1 VCF 27 days after starting therapy. Therefore, only the
L4 vertebral body was not involved, so the BMD data were
not included. One of the remaining 21 patients missed the
6-month BMD examination, and another missed the 12-
month BMD examination. Three patients in group B had
only one evaluable vertebral body for DXA examination, so
the BMD data were excluded. Five patients skipped the 6-
month, two skipped the 12-month, and two skipped the 18-
month DXA examination. The remaining 19 patients had at
least two evaluable BMD data for analysis.
In group A, the mean BMD was 0.5796±0.0816 g/cm
2
at baseline, 0.6548±0.1073 g/cm
2 after 6 months, 0.6840±
0.1161 g/cm
2 after 12 months, and 0.7054±0.1030 g/cm
2
after 18 months teriparatide treatment (Fig. 4), at which
time, spinal BMD had increased 21.7%. The BMDs and T-
scores increased markedly by the end of 6 months of
therapy and increased slowly and steadily from the 6th
month to the 18th month of treatment. The mean T-score
value was −3.76±0.71 at baseline, −3.16±0.60 after
6 months, −3.00±0.59 after 12 months, and −2.86±0.53
after 18 months of teriparatide treatment (p=0.000, all the
differences between baseline and 6 months, 6 and
12 months, and 12 and 18 months were significant).
In group B, the mean BMD was 0.6245±0.1026 g/cm
2
at baseline, 0.6281±0.0964 g/cm
2 after 6 months, 0.6582±
0.1027 g/cm
2 after 12 months, and 0.6705±0.0894 g/cm
2
after 18 months of antiresorptive treatment, at which
time, spinal BMD had increased 6.87%. The mean T-
score values were −3.43±0.73 at baseline, −3.36±0.64
after 6 months, −3.15±0.63 after 12 months, and −3.12±
0.57 after 18 months of treatment with antiresorptive
agents (p=0.066).
Discussion
Vertebral fractures are the most common fragility fracture in
osteoporotic patients and are associated with a 16%
reduction in expected 5-year survival. Studies show that
VCFs are often not diagnosed, and only about 30% of
VCFs come to medical attention [17]. Vertebroplasty and
kyphoplasty are minimally invasive procedures for the
treatment of VCFs and are used primarily for pain relief and
restoration of vertebral body height. Nonetheless, recent
studies have questioned the effects of vertebroplasty [18,
19]. Buchbinder et al. found vertebroplasty had no
beneficial effect compared with a sham procedure in
patients with painful osteoporotic VCFs at 1 week and at
1, 3, or 6 months after treatment. They demonstrated
vertebroplasty did not result in a significant advantage in
any measured outcome at any time point [18]. Kallmes et
al. demonstrated in a randomized controlled trial that
improvements in pain and pain-related disability associated
with osteoporotic VCFs in patients treated with vertebro-
plasty were similar to the improvements in a simulated
procedure without the use of cement (control group) [20].
PVP appeared to relieve pain effectively and restore
vertebral body height in most studies [3, 21]. Although
PVP relieves the pain of compression fractures, recurrent
back pain after PVP is common [21]. Among our group B
patients, the VAS score was 2.95±1.56 at month 12 and
3.14±1.58 at month 18 (p=0.329). The lack of statistical
significance between these two periods shows that pain
relief was not sustained. Teriparatide reduced fracture risk,
and in a published meta-analysis of clinical trials,
teriparatide-treated patients had a reduced incidence of
back pain relative to a placebo and antiresorptive drugs [22,
23]. Patients randomized to teriparatide had a reduced risk
of new or worsening back pain compared with patients
randomized to a placebo, hormone replacement therapy, or
Fig. 4 The mean lumbar spine BMD before and at 6, 12, and
18 months after treatment. Data are expressed as mean ± SD. The
BMD increased markedly in group A by the end of 6 months of
therapy, and continued to increase slowly and steadily from the 6th to
the 18th month of treatment. The increase in lumbar spine BMD was
marked in the teriparatide group (21.7% vs. 6.87%) after 18 months of
treatment. (*p<0.05,
★p<0.01) BMD bone mineral density
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antiresorptive and anabolic agents, particularly those with
teriparatide therapy, had a reduced risk of new or worsening
back pain. Fewer patients treated with teriparatide reported
new or worsening back pain, especially moderate and
severe back pain, compared with those treated with
alendronate [13, 24]. Teriparatide was more effective than
other drugs in reducing back pain and improving the quality
of life of postmenopausal osteoporotic women with VCFs
[25]. The mechanism of back pain reduction likely includes
a reduction in both severity and number of new VCFs [26]
and improvement in bone microarchitecture and quality
[13]. The VAS and JOA low back pain scores were
significantly better after 6 months of treatment. After
6 months, the VAS continued to decrease, and the JOA
score continued to increase; the difference between group A
and group B was statistically significant at 12 and
18 months of treatment (p<0.001).
Some biomechanical test data and clinical studies have
suggested patients who undergo vertebroplasty or kypho-
plasty had a greater risk of new VCFs compared with
patients with prior VCFs who did not undergo either
procedure [4]. Biomechanical test data demonstrated that
fractured vertebrae treated with bone cement are stiffer than
untreated vertebrae, and thus could transfer a greater load to
adjacent vertebral levels [27, 28]. An increased fracture rate
of the adjacent vertebrae has been observed after verte-
broplasty [8]. Specifically, following vertebroplasty,
patients are at increased risk of new-onset adjacent-level
fractures and, when these fractures occur, they occur much
sooner than non-adjacent-level fractures [6, 8].
Antiresorptive agents (alendronate, risedronate, raloxi-
fene, and calcitonin) are widely used to treat osteoporosis.
In a randomized trial of daily therapy with raloxifene for
24 months, the mean difference in the change in BMD
between the women receiving 60 mg of raloxifene per day
and those receiving a placebo was 2.4%±0.4% for the
lumbar spine, 2.4%±0.4% for the total hip, and 2.0%±
0.4% for the total body [29]. Treatment with 10 mg of
alendronate daily for 10 years produced mean increases in
BMD of 13.7% at the lumbar spine [30]. A randomized
double-blind trial comparing the effect of teriparatide to that
of alendronate sodium on BMD, non-vertebral fracture
incidence, and bone turnover in 146 postmenopausal
women with osteoporosis revealed that at 3 months,
teriparatide was significantly more effective at increasing
lumbar spine BMD than alendronate (p<0.001). Lumbar
spine BMD increased by 12.2% in the teriparatide group
and 5.6% in the alendronate group after a mean treatment
period of 14 months [31]. In our study, the percentage
increase in lumbar spine BMD was 21.7% after 18 months
of teriparatide treatment and 6.87% after 18 months of
treatment with antiresorptive agents. Thus, the teriparatide-
mediated BMD increase was much greater than that of
antiresorptive therapy.
Currently, the extent to which the anti-fracture efficacy
of antiresorptive drugs is related to changes in BMD is
under debate. Wasnich and Miller have provided a model
that predicted that treatments increasing spine BMD by 8%
would reduce the risk of VCFs by 54% [32]. Data from
clinical trials showed that raloxifene and alendronate
reduced the risk of vertebral fracture by 40% to 50% after
3 years of treatment [9, 10]. Most new VCFs occurred
within 3 months of PVP [6–8]. Although antiresorptive
agents increased BMD and improved the bone quality of
the lumbar spine, they were slow acting and did not rapidly
increase BMD and guard against the development of new-
onset VCFs after PVP.
Investigators have suggested that the gain in BMD with
alendronate and other antiresorptive agents may be
achieved by a remodeling of spaces, that is, reducing bone
turnover without a true stimulation of bone formation [33].
Teriparatide (rDNA origin) injection (recombinant human
parathyroid hormone, PTH [1–34]) directly stimulates bone
formation via stimulating bone remodeling, increases
BMD, and restores bone architecture and integrity. In
contrast, bisphosphonates reduce bone resorption and
increase BMD [31, 34]. Studies have shown that teripara-
tide induces large increases in biochemical markers of bone
formation after 1 month of therapy, followed by a delayed
increase in bone resorption markers [35]. These data show
that teriparatide treatment for postmenopausal women with
osteoporosis significantly increased cancellous bone volume
and connectivity, improved trabecular morphology with a
shift toward a more plate-like structure, and increased cortical
bonethickness.Thesechangesincancellousandcorticalbone
morphology should improve biomechanical competence and
are consistent with the substantially reduced incidences of
vertebral and non-vertebral fractures during administration of
teriparatide [36].
Two-dimensional histomorphometric and three-
dimensional micro-computed tomography (CT) parameters
were measured along with lumbar spine BMD at baseline and
12or18monthsafterteriparatidetreatment.Sinceincreasesin
BMD are correlated with improvements in trabecular micro-
architecture in the iliac crests of patients taking teriparatide
treatment, improvements in trabecular bone microarchitecture
could be one of the mechanisms explaining how BMD
increases improve bone strength during teriparatide treatment
[37]. Teriparatide treatment results in an increase in BMD
and is a potentially useful therapy for osteoporosis in men
and for glucocorticoid-induced osteoporosis [38]. The
subcutaneous daily dose of teriparatide (20 μg) decreased
the occurrence of new VCFs in white women (70 years of
age) by 65%, in a large randomized, double-blind, placebo-
controlled trial. Moderate-to-severe fractures and multiple
Osteoporos Int (2012) 23:1613–1622 1619vertebral fractures were reduced by 90% and 77%, respec-
tively. These results indicate that the clinical effects of
teriparatide were consistent in both older and younger
women. Age does not affect the safety and efficacy of
teriparatide in postmenopausal women with osteoporosis
[39]. In our study, teriparatide-mediated fracture risk reduc-
tion was 78.57%. Patients treated with teriparatide had a
significantly lower risk of new-onset VCFs (OR=0.21; 95%
CI, 0.02–2.1).
In order to evaluate therapeutic effect, serial measure-
ments of BMD are necessary. There is no absolutely reliable
skeletal site or region of interest for monitoring these
changes. The International Society for Clinical Densitom-
etry recommends the lumbar spine as the most preferred
bone site for monitoring serial changes in BMD [40, 41].
Even though one patient in group A and three patients in
group B had only one usable vertebral body from L1 to L4
for the DEXA examination, we still preferred to use the
lumbar spine for BMD monitoring of treatment.
Furthermore, the beneficial effects of teriparatide on
vertebral fracture prevention and BMD persisted after
treatment cessation. Teriparatide had a sustained effect in
reducing the risk of non-vertebral fragility fractures for 18–
30 months after discontinuation of treatment [42, 43].
As teriparatide is expensive, its use at the moment
should be limited to patients with more severe forms of
osteoporosis, usually with the presence or history of one or
more fractures, because those patients are at high risk for
subsequent fractures. We used teriparatide to treat new-
onset adjacent VCFs after vertebroplasty and had good
therapeutic pain relief and fracture prevention. Teriparatide
is generally well tolerated, and treatment compliance rates
are favorable. However, current limitations on the length of
treatment and the high acquisition cost mean that teripara-
tide is best reserved for the treatment of patients with
osteoporosis at high risk of fracture, or for patients with
osteoporosis that have unsatisfactory responses to or
intolerance of other osteoporosis therapies [38].
The limitations of the present study include the patient
selection criteria. Some conditions, including degenerative
lumbar spine disorder, long-term systemic disease, and
previous leg fracture could affect the outcome of VCF
treatment. Some patients in Taiwan seek out herbal
medicines or folk remedies for back pain or other diseases,
and some of these folk prescriptions include steroid, which
can impact the therapeutic effect. Sometimes, patients
suffering from a second VCF will seek out treatment in
other hospitals. Many patients in our two groups had also
undergone PVP in other hospitals and visited our hospital
for medical treatment when new-onset VCFs occurred.
Precise data on previous treatment for osteoporosis and
medical history were difficult to obtain. The cost of
teriparatide is high, and it is offered by Taiwan's Bureau
of National Health Insurance for 18 months to severe
osteoporostic patients. Only a few patients continued with
self-paid treatment after the 18 months. Therefore, the
treatment period was limited. Since the administration
routes for teriparatide (subcutaneous injection) and anti-
resorptive agents (oral intake) are different, it is difficult to
perform a double-blind study. An evaluation of pain relief
should consider the dosage of analgesics, but complicated
pharmacodynamics, side effects, and drug compliance with
different analgesics may flaw the evaluation. The result of
such studies would help patients choose the procedure that
is optimal for them in terms of pain relief, fracture
prevention, treatment safety and cost.
Conclusion
Fracture prevention and pain relief are the primary
treatment goals for patients with osteoporotic VCFs.
Although PVP can provide immediate pain relief, the
procedure accelerates the failure rate in the adjacent
vertebral body. Antiresorptive agents do not significantly
and rapidly increase BMD and reduce the risk for VCFs.
Most post-vertebroplasty new-onset adjacent VCFs occur
within 2–3 months, and antiresorptive agents do not protect
against their development. In our study, teriparatide-
mediated BMD was significantly increased by 21.7% after
18 months of treatment, and fracture risk reduction was
78.57%. Teriparatide therapy significantly increased JOA
and decreased VAS scores. The therapeutic effect of
teriparatide is better than that of vertebroplasty combined
with an antiresorptive treatment and is a potentially useful
therapy for new-onset adjacent compression fractures after
vertebroplasty.
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